Nivolumab
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 13690 publications
Fulminant blood sugar increase - a rare but life-threatening course
Journal: Praxis
Published: September 08, 2026
Correction: Multimodal sequencing identifies synergistic mechanisms driving resistance to neoadjuvant nivolumab treatment in hepatocellular carcinoma.
Journal: Molecular cancer
Published: September 04, 2026
Pathological Complete Response and Conversion Gastrectomy after Nivolumab Plus FOLFOX in an 84-Year-Old Man with MSI-High Gastric Cancer Presenting as a Sister Mary Joseph Nodule: A Case Report.
Journal: Internal medicine (Tokyo, Japan)
Published: September 02, 2026
Successful treatment of multiple phototherapy-induced cutaneous squamous cell carcinomas with nivolumab monotherapy.
Journal: European journal of dermatology : EJD
Published: August 28, 2026
A multicenter pilot study of nivolumab with drug-eluting bead transarterial chemoembolization in patients with liver-limited hepatocellular carcinoma.
Journal: ESMO gastrointestinal oncology
Published: August 28, 2026
Biopsied Cutaneous Adverse Effects of PD-1 and PD-L1 Checkpoint Inhibitors and Progression-free Survival: A Retrospective Case Series of 75 Patients.
Journal: The American Journal of dermatopathology
Published: August 27, 2026
B-cell depletion improves therapeutic index of combination checkpoint blockade in patients with advanced melanoma.
Journal: The Journal of clinical investigation
Published: August 25, 2026
The influence of LINC00511 and MDM2/MDM4 in lung carcinoma: Implications for immunological therapeutic strategies.
Journal: Pakistan journal of pharmaceutical sciences
Published: August 22, 2026
Cost‑effectiveness of first‑line immunotherapy-based combination regimens for advanced renal cell carcinoma in China and the United States.
Journal: Human vaccines & immunotherapeutics
Published: August 22, 2026
Humanized Anti-PD-1 Antibodies Generated Using The Conditional Kernel-Elastic Autoencoder.
Journal: bioRxiv : the preprint server for biology
Published: August 20, 2026
Cost-effectiveness of perioperative pembrolizumab plus enfortumab vedotin for cisplatin-ineligible or cisplatin-declining patients with muscle-invasive bladder cancer in the United States.
Journal: Journal of medical economics
Published: August 18, 2026
Last Updated: 09/26/2026